SU-E-T-442: Sensitivity of Quality Assurance Tools to Delivery Errors On a Magnetic Resonance-Imaging Guided Radiation Therapy (MR-IGRT) System

2014 ◽  
Vol 41 (6Part18) ◽  
pp. 327-328 ◽  
Author(s):  
V Rodriguez ◽  
H Li ◽  
D Yang ◽  
R Kashani ◽  
H Wooten ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Quality Assurance ◽  
Radiation Therapy ◽  
Magnetic Resonance ◽  
Resonance Imaging

Acceptance Testing and Quality Assurance Procedures for Magnetic Resonance Imaging Facilities

10.37206/101 ◽  
2010 ◽  
Author(s):  
Edward Jackson ◽  
Michael Bronskill ◽  
Dick Drost ◽  
Joseph Och ◽  
Robert Pooley ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Quality Assurance ◽  
Magnetic Resonance ◽  
Acceptance Testing ◽  
Resonance Imaging

scholarly journals NIMG-33. CHANGES IN MAGNETIC RESONANCE IMAGING AFTER PROTON BOOST THERAPY FOR GLIOBLASTOMA WITH AND WITHOUT TUMOR TREATING FIELDS THERAPY

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii155-ii155
Author(s):  
Hanna Goett ◽  
Alexandra Jensen ◽  
Tobias Struffert ◽  
Eberhard Uhl ◽  
Marco Stein
Keyword(s):  
Magnetic Resonance Imaging ◽  
Radiation Therapy ◽  
Magnetic Resonance ◽  
Contrast Enhancement ◽  
Median Overall Survival ◽  
Progressive Disease ◽  
Tumor Resection ◽  
Resonance Imaging ◽  
Tumor Treating Fields ◽  
Magnetic Resonance Imaging Mri

Abstract BACKGROUND Tumor treating fields (TTFields) are an approved glioblastoma (GBM) treatment modality that demonstrated a significant improved median overall survival in newly diagnosed GBM patients. Data about morphologic changes in serial magnetic resonance imaging (MRI) for patients with a combination therapy of TTFields and proton boost therapy does not exist. METHODS Twenty-two patients were included in this study. All patients were treated with initial tumor resection followed by combined chemo- and radiation therapy. Radiation therapy was performed with 50.0 Gy photons and a proton boost with 10 Gy equivalent (Gy(RBE)). 11 patients were additionally treated with TTFields. RESULTS A new increase in contrast enhancement and/or a progress in the T2 FLAIR hyperintensity was observed in 54.5% (N=12) at 3 months and in 31.8% (N=7) at 6 months. No differences were observed between patients with and without TTFields therapy at 3 months [63.6% (N=7) vs. 45.5% (N=5); P=0.392] and at 6 months [27.3 (N=3) vs. 36.3% (N=4); P=0.647). By the RANO criteria a progressive disease (PD) was observed in 6 patients (27.3%) at 3 months and in 7 patients (31.8%) at 6 months. Pseudoprogression (PP) was observed in in 36.4% (N=8) at months and in 27.3% (N=6) at 6 months. Neither for PD at 3 months [36.4% (N=4) vs. 18.2% (N=2); P=0.338] or at 6 months [36.4% (N=4) vs. 27.3% (N=3); P=0.647), nor for PP at 3 months [45.5% (N=5) vs. 27.2% (N=3); P=0.375] or at 6 months [18.2% (N=2) vs. 36.4% (N=4); P=0.338] differences for patients with and without TTFields therapy were found. CONCLUSION Increased contrast enhancement and/or increased T2 FLAIR MRI hyperintensity after proton boost therapy are common. Furthermore, the rates for new contrast enhancement, PD, and PP after photon therapy with and without additional TTFields therapy are comparable.

Sign in / Sign up

Export Citation Format

Share Document